Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients

血浆代谢组学能够区分2型糖尿病和冠心病特异性代谢紊乱,并识别糖尿病患者冠心病风险增加的潜在生物标志物。

阅读:1

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major driver of coronary artery disease (CAD). Prior studies often conflate T2DM- and CAD-specific metabolic alterations, limiting insights into CAD pathogenesis in T2DM. This study aimed to distinguish CAD-unique signatures from T2DM-specific dysmetabolism, and to identify potential metabolic biomarkers for CAD risk escalation in T2DM patients. METHODS: We performed an untargeted plasma metabolomic study with 123 healthy controls (HCs), 50 T2DM patients without CAD, and 155 T2DM patients with CAD. T2DM_CAD was defined as T2DM diagnosed at least 5 years prior to CAD, with coronary angiography-confirmed stenosis (> 30%) in major coronary arteries. Differential metabolites were identified via intergroup comparisons, with T2DM-specific and CAD-specific signatures distinguished based on unique expression patterns. Machine learning models were developed to evaluate the discriminatory performance of these metabolites for CAD. RESULTS: Plasma metabolomic profiling identified distinct metabolic patterns across the three cohorts. Metabolites specific to T2DM were enriched in carbohydrates and certain lipid species, reflecting disturbances in glucose and lipid metabolism. CAD-specific metabolites were predominantly lipids and organic acids, with notable involvement in amino acid and fatty acid metabolic pathways. Several metabolites changed progressively from HCs through T2DM to T2DM_CAD, reflecting advancing metabolic dysregulation, whereas others showed opposing trends, suggesting compensatory or protective adaptations. Integration of key metabolites with clinical parameters in machine learning models effectively distinguished between study groups, demonstrating promising performance for CAD risk assessment in T2DM patients. CONCLUSIONS: These findings disentangle T2DM- and CAD-specific metabolic disturbances and identify escalation/de-escalation features of CAD risk in diabetic patients, which are potential candidates for future risk stratification pending validation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。